Ultragenyx Pharmaceutical and Arcturus Therapeutics have expanded their collaboration to discover and develop mRNA, DNA & siRNA therapeutics for up to 12 rare disease targets.
- In connection with amendment to license pact, Ultragenyx made $6 million cash upfront payment to Arcturus and Ultragenyx is purchasing 2.4 million shares of Arcturus’ stock at $10/share
- Ultragenyx has an option to buy another 600,000 shares of Arcturus’ stock at $16/share
- Ultragenyx will become Arcturus’ largest shareholder with General Counsel Karah Parschauer joining Arcturus’ board & CEO Emil Kakkis joining as an Arcturus board observer
- Investigational New Drug application for mRNA therapeutic program, UX053, ...